GrenadaTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.44 (0.43–0.44)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) <0.01 (<0.01–<0.01) 2.9 (1.2–5.2)
Incidence  (includes HIV+TB) <0.01 (<0.01–<0.01) 1.3 (1–1.5)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.11 (0.08–0.14)
         
Case detection, all forms (%) 0 (0–0)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
0 (0–0) 0 (0–0)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 0   0
Pulmonary, clinically diagnosed 0   0
Extrapulmonary 0   0
       
Total new and relapse 0    
Previously treated, excluding relapses 0    
Total cases notified 0    
Among 0 new and relapse cases:
0 cases aged under 15 years;
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 0 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 0  
HIV-positive TB patients 0  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (100) 1
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-30 Data: www.who.int/tb/data